SYS6045
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 18, 2025
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=266 | Active, not recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
New P1/2 trial • Solid Tumor
1 to 1
Of
1
Go to page
1